| SC 13G/A | 2020-03-10 | ORBIMED ADVISORS LLC | CTI BIOPHARMA CORP | 9,520,000 | 12.9% | EDGAR |
| SC 13D/A | 2020-03-04 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 6,795,120 | 11.0% | EDGAR |
| SC 13D/A | 2020-02-13 | Growth Equity Opportunities V, LLC | CTI BIOPHARMA CORP | 3,750,000 | 6.5% | EDGAR |
| SC 13G/A | 2020-02-13 | Stonepine Capital Management, LLC | CTI BIOPHARMA CORP | 3,613,600 | 6.2% | EDGAR |
| SC 13D/A | 2020-02-04 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 6,795,120 | 11.0% | EDGAR |
| SC 13G/A | 2019-02-13 | Stonepine Capital Management, LLC | CTI BIOPHARMA CORP | 5,726,579 | 9.9% | EDGAR |
| SC 13D | 2018-02-20 | Growth Equity Opportunities V, LLC | CTI BIOPHARMA CORP | 3,750,000 | 6.0% | EDGAR |
| SC 13D/A | 2018-02-12 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 6,795,120 | 10.7% | EDGAR |
| SC 13G/A | 2018-02-05 | Baxalta Inc | CTI BIOPHARMA CORP | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-01-12 | Stonepine Capital Management, LLC | CTI BIOPHARMA CORP | 2,150,000 | 5.0% | EDGAR |
| SC 13G | 2017-06-22 | Stonepine Capital Management, LLC | CTI BIOPHARMA CORP | 2,307,446 | 7.6% | EDGAR |
| SC 13G | 2017-06-15 | ORBIMED ADVISORS LLC | CTI BIOPHARMA CORP | 5,000,000 | 11.6% | EDGAR |
| SC 13D/A | 2017-06-14 | BIOTECHNOLOGY VALUE FUND L P | CTI BIOPHARMA CORP | 3,566,549 | 8.3% | EDGAR |
| SC 13G/A | 2017-02-06 | Baxalta Inc | CTI BIOPHARMA CORP | 1,567,398 | 5.5% | EDGAR |
| SC 13G/A | 2017-01-31 | NB Public Equity K/S | CTI BIOPHARMA CORP | 13,566,354 | 4.8% | EDGAR |
| SC 13G/A | 2016-08-10 | FMR LLC | CTI BIOPHARMA CORP | 5,122,260 | 1.8% | EDGAR |
| SC 13G/A | 2016-06-07 | Baxalta Inc | CTI BIOPHARMA CORP | 15,673,981 | 5.5% | EDGAR |
| SC 13G/A | 2016-04-11 | FMR LLC | CTI BIOPHARMA CORP | 24,664,248 | 8.8% | EDGAR |
| SC 13G/A | 2016-02-29 | Baxalta Inc | CTI BIOPHARMA CORP | 15,673,981 | 6.8% | EDGAR |
| SC 13G | 2016-02-12 | Baxalta Inc | CTI BIOPHARMA CORP | 15,673,981 | 14.8% | EDGAR |